根据公告，业绩变动主要系二价HPV疫苗产品受多重因素影响，出现近效期无法销售及库存减值，预计 影响净利润5—6亿元左右。同时，九价HPV疫苗尚处于市场准入阶段，利润贡献尚未充分体现。此外， 诊断板块亦受集采降价及医保政策影响，收入利润同比下滑。 北京商报讯(记者王寅浩宋雨盈)1月29日，万泰生物（603392）发布2025年业绩预告，预计2025年归属 于母公司所有者的净亏损为3.3亿—4.1亿元，同比转亏。预计实现归属于母公司所有者的扣除非经常性 损益的净亏损为5.3亿—6.6亿元。 ...

Group 1 - Meinian Health plans to participate in the restructuring of Zhejiang Bangjie Holdings, aiming to become the controlling shareholder after the completion of the restructuring [3] - Baiyin Nonferrous Metals reported that the revenue from gold and silver products accounted for a low proportion of total operating income, with gold sales contributing 18.67% and silver sales 4.54% in the first half of 2025 [4] - Tiens Wind Power decided to implement a long-term production suspension for six wholly-owned subsidiaries to optimize resource allocation and focus on core businesses [5] Group 2 - Tongling Nonferrous Metals indicated significant uncertainty in the price fluctuations of its main products, with a low self-sufficiency rate for copper concentrate posing supply stability risks [6] - *ST Aowei received a notice of termination of listing due to its market capitalization falling below 500 million yuan for twenty consecutive trading days [7] - Foton Motor expects a net profit increase of approximately 1551% year-on-year for 2025, driven by sales growth in new energy vehicles and overseas markets [9] Group 3 - Beimo High-tech anticipates a net profit increase of 1076.16% to 1261.87% for 2025, supported by cost control and reduced credit impairment losses [10] - Zhongke Sanhuan forecasts a net profit growth of 566.23% to 899.35% for 2025, attributed to technological innovation and improved operational efficiency [12] - Wancheng Group expects a net profit increase of 222.38% to 266.94% for 2025, driven by growth in its retail business and improved sales margins [13] Group 4 - Huayi Technology anticipates a net profit increase of 191.52% to 330.34% for 2025, benefiting from product optimization and cost reduction measures [14] - Nanmo Biology expects a net profit growth of 269.49% to 423.44% for 2025, supported by increased revenue in the biopharmaceutical sector and improved cost control [15] - Baiao Saitu forecasts a net profit increase of 384.26% to 443.88% for 2025, driven by expansion in overseas markets and recovery in the domestic biopharmaceutical industry [16] Group 5 - Hailanxin expects a net profit increase of 387.47% to 631.2% for 2025, supported by advancements in technology and increased market share in marine observation [17] - Panjiang Co. anticipates a net profit growth of 205.3% to 264.83% for 2025, driven by increased coal production and reduced costs [18] - Huaguang New Materials expects a net profit increase of 104.67% to 141.88% for 2025, with significant growth in the electronic sector [20] Group 6 - Guo Sheng Securities forecasts a net profit increase of 25.44% to 67.25% for 2025, supported by active capital market participation and growth in various business segments [25] - Shengyi Technology expects a net profit growth of 87% to 98% for 2025, driven by increased sales of copper-clad laminates [26] - Sifutian anticipates a net loss of 30 million to 45 million yuan for 2025, although this represents a significant reduction in losses compared to the previous year [27] Group 7 - Maanshan Steel expects a net loss of 1.9 billion to 2.5 billion yuan for 2025, with a substantial reduction in losses compared to the previous year [28] - Shennong Seed Industry forecasts a net profit of 90 million to 120 million yuan for 2025, marking a turnaround from previous losses [30] - Jifeng Co. anticipates a net profit of 410 million to 495 million yuan for 2025, achieving a turnaround from losses [31]

北京商报讯（记者 丁宁）1月29日晚间，万泰生物（603392）发布2025年业绩预告显示，预计2025年实 现归属净利润为-3.3亿元至-4.1亿元，同比由盈转亏。 万泰生物表示，疫苗板块方面，受国内疫苗集采政策、行业竞争、消费者疫苗犹豫等多重因素影响，国 内疫苗市场整体承压，行业收入、利润均大幅下滑。对于公司而言，在收入端以及生产端都面临严峻挑 战，二价HPV疫苗受默沙东九价HPV疫苗扩龄、政府采购大幅降价、消费需求不足等影响，导致公司二 价HPV疫苗产品出现近效期无法销售、库存无法变现的不利影响。公司从夯实资产质量和消除对经营影 响的角度，对市场端和生产端产品进行积极处理，并计提相应减值准备。整体预计影响净利润5亿元至6 亿元左右，是本期利润大幅下滑的原因之一。 万泰生物提到，为应对二价HPV疫苗的不利影响，公司积极开拓国际市场，并加快创新产品的研发和上 市，取得了一定的成效。国际市场方面，2025年，二价HPV疫苗营收实现倍数级增长；国内首家创新产 品九价HPV疫苗成功上市，并积极推广。截至本报告期末，公司九价HPV疫苗已完成27个省份的准入落 地，并持续加快全国3万多个POV终端的覆盖及矩阵布局，加 ...

Earnings Forecasts - Shengyi Electronics expects a net profit of 1.431 billion to 1.513 billion yuan in 2025, an increase of 331.03% to 355.88% year-on-year [1] - Tigermed anticipates a net profit of 830 million to 1.23 billion yuan in 2025, representing a growth of 105% to 204% year-on-year [2] - Shunbo Alloy forecasts a net profit of 210 million to 270 million yuan in 2025, with an increase of 222.96% to 315.23% year-on-year [3] - Jinkong Electric expects a net profit of 155 million to 195 million yuan in 2025, reflecting a growth of 383.21% to 507.9% year-on-year [9] - Baiao Saitu anticipates a net profit of 162 million to 182 million yuan in 2025, with a year-on-year increase of 384.26% to 443.88% [18] - Panjiang Co. expects a net profit of 318 million to 380 million yuan in 2025, representing a growth of 205.30% to 264.83% year-on-year [38] Loss Forecasts - Liaoning Energy predicts a net loss of 273 million to 410 million yuan in 2025, compared to a profit of 202 million yuan in the previous year [5] - Anbotong anticipates a net loss of 114 million to 165 million yuan in 2025, with a revenue decrease of 19.65% to 27.25% [7] - Wantai Bio forecasts a net loss of 330 million to 410 million yuan in 2025, compared to a profit of 106 million yuan in the previous year [12] - Xingyun Co. expects a net loss of 155 million to 230 million yuan in 2025, compared to a loss of 82.44 million yuan in the previous year [20] - Huaxing Co. anticipates a net loss of 800 million to 1.2 billion yuan in 2025, with a reduction in loss compared to 1.67 billion yuan in the previous year [46] New Product Approvals - Hengrui Medicine received acceptance for a new indication application for its innovative drug, combining Carrelizumab and Apatinib for treating unresectable liver cancer [4] - Tianen Kang's subsidiary received a drug registration acceptance notice for Lidocaine and Prilocaine aerosol [31] - Lisheng Pharmaceutical announced that its Aminophylline tablets passed the consistency evaluation for generic drugs [40] Share Buyback Plans - Hengyuan Coal Power plans to repurchase shares with a total amount not less than 200 million yuan and not exceeding 250 million yuan [13] Contract Wins - China Communication Signal Co. won contracts totaling approximately 5.26 billion yuan for 21 important projects in the railway and urban rail transit markets [37]

格隆汇1月29日丨万泰生物(603392.SH)在投资者互动平台表示，公司产品近年有出口欧盟国家，是以境 内主体直接向欧盟客户出口为主。 ...

格隆汇1月29日丨万泰生物(603392.SH)在投资者互动平台表示，公司产品近年有出口欧盟国家，是以境 内主体直接向欧盟客户出口为主。 ...

（记者 王晓波） 每经头条（nbdtoutiao）——水贝黄金平台"杰我睿"兑付危机调查：40倍杠杆对赌，金价越涨平台越 亏！老板自称"还在深圳"，投资者：兑付方案本金打两折，无法接受 每经AI快讯，万泰生物1月29日晚间发布业绩预告，预计2025年年度实现归属于母公司所有者的净利润 为-4.1亿元到-3.3亿元，与上年同期相比，将出现亏损。业绩变动主要原因是：疫苗板块，受国内疫苗 集采政策、行业竞争、消费者疫苗犹豫等多重因素影响，国内疫苗市场整体承压，行业收入、利润均大 幅下滑。对于公司而言，在收入端以及生产端都面临严峻挑战，二价HPV疫苗受默沙东九价HPV疫苗扩 龄、政府采购大幅降价、消费需求不足等影响，导致公司二价HPV疫苗产品出现近效期无法销售、库存 无法变现的不利影响。公司从夯实资产质量和消除对经营影响的角度，对市场端和生产端产品进行积极 处理，并计提相应减值准备。整体预计影响净利润5-6亿元左右，是本期利润大幅下滑的原因之一。为 应对二价HPV疫苗的不利影响，公司积极开拓国际市场，并加快创新产品的研发和上市，取得了一定的 成效。国际市场方面，2025年，二价HPV疫苗营收实现倍数级增长；国内首家创 ...

证券代码：603392 证券简称：万泰生物 公告编号：2026-006 北京万泰生物药业股份有限公司 2025 年年度业绩预亏公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 业绩预告的具体适用情形：净利润为负值。 北京万泰生物药业股份有限公司（以下简称"公司"）预计2025年年度 实现归属于母公司所有者的净利润为-41,000万元到-33,000万元。 公司预计2025年年度实现归属于母公司所有者的扣除非经常性损益的净 利润为-66,000万元到-53,000万元。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）业绩预告情况 1、经财务部门初步测算，预计2025年年度实现归属于母公司所有者的净利 润为-41,000万元到-33,000万元，与上年同期相比，将出现亏损。 2、预计2025年年度实现归属于母公司所有者的扣除非经常性损益的净利润 为-66,000万元到-53,000万元。 3、本次业绩预告未经注册会计师审计。 二、上年同期业绩情况 （一）利润总额： ...

南财智讯1月29日电，万泰生物发布业绩预亏公告，公司预计2025年年度实现归属于母公司所有者的净 利润为-33,000万元至-41,000万元。报告期内，公司利润出现大幅下滑、整体亏损主要受两个方面的影 响：（一）疫苗板块，受国内疫苗集采政策、行业竞争、消费者疫苗犹豫等多重因素影响，国内疫苗市 场整体承压，行业收入、利润均大幅下滑。对于公司而言，在收入端以及生产端都面临严峻挑战，二价 HPV疫苗受默沙东九价HPV疫苗扩龄、政府采购大幅降价、消费需求不足等影响，导致公司二价HPV疫 苗产品出现近效期无法销售、库存无法变现的不利影响。公司从夯实资产质量和消除对经营影响的角 度，对市场端和生产端产品进行积极处理，并计提相应减值准备。整体预计影响净利润5-6亿元左右， 是本期利润大幅下滑的原因之一。（二）诊断板块，受国家诊断试剂行业集采降价以及检验套餐解绑等 医保政策影响，公司诊断收入及利润同比下滑；公司持续加大自主研发投入，加速装机及流水线等大项 目驱动，带动传染病及甲状腺功能等特色检测业务实现同比两位数增长。 ...

每经AI快讯，1月29日，万泰生物（603392）(603392.SH)公告称，预计2025年归属于上市公司股东的净 利润为-4.10亿元至-3.30亿元，上年同期盈利1.06亿元，同比转亏。主要因二价HPV疫苗受集采降价、消 费需求不足等影响，出现近效期无法销售及库存减值，预计影响净利润约5亿–6亿元；九价HPV疫苗虽 已上市并加速准入，但报告期内利润贡献尚未充分体现；诊断板块亦受集采降价及医保政策影响，收入 利润同比下滑。 ...